细胞毒性NK细胞阻碍免疫排斥表型黑色素瘤对检查点免疫治疗的应答
该研究分析黑色素瘤患者免疫检查点阻断(ICB)治疗前后配对活检的免疫景观,发现无应答者早期治疗活检中细胞毒性NK细胞显著增加。空间多组学显示NK细胞在应答病灶中与CD8+ T细胞共定位,但在无应答病灶中被排除于肿瘤实质。在小鼠模型中药物清除NK细胞可解除免疫排斥并促进ICB后肿瘤清除,机制涉及CX3CR1招募NK细胞抑制CD8+ T细胞浸润和抗肿瘤功能。
要点
- 无应答者ICB早期治疗活检中细胞毒性NK细胞显著增加
- NK细胞在无应答病灶中被排除于肿瘤实质,在应答病灶中与CD8+ T细胞共定位
- 小鼠模型中清除NK细胞可解除免疫排斥并促进ICB后肿瘤清除
核心结论
- 靶向NK细胞生物学可释放免疫排斥表型肿瘤中CD8+ T细胞的招募和抗肿瘤活性,为这一大量患者群体提供潜在治疗途径。
- 免疫排斥是约半数无应答患者对ICB原发性耐药的机制。
研究设计与样本
- 分析接受ICB治疗的黑色素瘤患者配对治疗前和早期治疗活检的免疫景观。
- 采用空间多组学分析NK细胞与CD8+ T细胞的空间分布。
- 使用展现免疫排斥表型的独特黑色素瘤小鼠模型进行药物清除NK细胞实验。
主要发现
- 无应答者早期治疗活检中细胞毒性NK细胞较治疗前显著增加。
- 空间多组学显示NK细胞在应答病灶中与CD8+ T细胞共定位于瘤床,但在无应答病灶中被排除于肿瘤实质。
- 小鼠模型中药物清除NK细胞后,ICB暴露下肿瘤核心出现免疫浸润和肿瘤清除。
- 机制上NK细胞经趋化因子受体CX3CR1被主动招募至免疫排斥区域,抑制CD8+ T细胞的肿瘤浸润和抗肿瘤功能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Immune checkpoint blockade (ICB) has revolutionized cancer treatment. Unfortunately, the inability of lymphocytes to infiltrate the tumor nest, a phenomenon known as immune exclusion, drastically limits ICB responsiveness. Analyzing the immune landscape of matched pre- and early on-treatment biopsies of patients with melanoma undergoing ICB therapy, we observed a significant increase in cytotoxic NK cells in early on-treatment biopsies from nonresponders. Spatial multiomic analyses revealed that, although NK cells colocalized with CD8+ T cells within the tumor bed in responding lesions, they were excluded from the tumor parenchyma in nonresponding lesions. Strikingly, pharmacologic depletion of NK cells in a unique melanoma mouse model exhibiting an immune-excluded phenotype unleashed immune infiltration of the tumor core and tumor clearance upon ICB exposure. Mechanistically, we show that NK cells are actively recruited to immune-excluded areas upon ICB exposure via the chemokine receptor CX3CR1 to suppress tumor infiltration and antitumor function of CD8+ T cells. SIGNIFICANCE: Immune exclusion is responsible for intrinsic resistance to ICB in about half of nonresponder patients. Our unexpected observation that targeting NK cell biology unleashes the recruitment and antitumor activity of CD8+ T cells in tumors with an immune-excluded phenotype offers a potential therapeutic avenue for this large patient population. See related commentary by Galvez-Cancino et al., p. 1777 See related article by Song et al., p. 1835.
引用
- Pozniak J, Roda N, Landeloos E, et al. Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype. Cancer Discov. 2025. PMID: 40530504. doi:10.1158/2159-8290.CD-24-1208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。